See more : Freelance.com SA (ALFRE.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Torrent Pharmaceuticals Limited (TORNTPHARM.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Torrent Pharmaceuticals Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Energoinstal S.A. (ENI.WA) Income Statement Analysis – Financial Results
- Public Joint Stock Company “M.video” (MVID.ME) Income Statement Analysis – Financial Results
- Stella-Jones Inc. (STLJF) Income Statement Analysis – Financial Results
- Innovators Facade Systems Limi (INNOVATORS.BO) Income Statement Analysis – Financial Results
- Shengjing Bank Co., Ltd. (2066.HK) Income Statement Analysis – Financial Results
Torrent Pharmaceuticals Limited (TORNTPHARM.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.torrentpharma.com
About Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. It offers products in various therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, women healthcare, diabetology, pain management, gynecology, oncology, and anti-infective, as well as provides vitamins, minerals, and nutrients. The company also provides contract manufacturing services. It has licensing collaborations of Baricitinib, Molnupiravir, and Paxlovid for its Covid portfolio. Torrent Pharmaceuticals Limited was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 106.05B | 94.64B | 84.19B | 78.86B | 77.80B | 74.62B | 58.57B | 56.72B | 65.19B | 45.79B | 40.32B | 30.49B | 25.94B | 21.22B | 19.16B | 16.31B | 13.55B | 12.99B | 9.67B | 5.48B |
| Cost of Revenue | 59.30B | 27.35B | 25.37B | 22.35B | 22.53B | 23.22B | 17.77B | 18.89B | 16.48B | 14.75B | 13.00B | 9.68B | 9.81B | 6.97B | 5.71B | 5.35B | 3.20B | 4.53B | 3.65B | 1.93B |
| Gross Profit | 46.76B | 67.29B | 58.81B | 56.51B | 55.27B | 51.40B | 40.80B | 37.84B | 48.71B | 31.04B | 27.32B | 20.81B | 16.13B | 14.25B | 13.45B | 10.95B | 10.35B | 8.45B | 6.02B | 3.55B |
| Gross Profit Ratio | 44.09% | 71.10% | 69.86% | 71.66% | 71.05% | 68.89% | 69.66% | 66.70% | 74.72% | 67.80% | 67.75% | 68.25% | 62.18% | 67.18% | 70.20% | 67.18% | 76.36% | 65.08% | 62.29% | 64.76% |
| Research & Development | 5.27B | 312.70M | 386.50M | 251.80M | 925.10M | 5.38B | 3.44B | 3.59B | 134.00M | 149.20M | 173.30M | 242.90M | 566.42M | 1.39B | 1.20B | 1.12B | 971.57M | 770.15M | 602.46M | 513.83M |
| General & Administrative | 7.72B | 6.14B | 5.55B | 5.79B | 6.07B | 6.11B | 5.85B | 4.54B | 2.15B | 2.16B | 1.58B | 1.36B | 2.53B | 5.92B | 4.88B | 4.68B | 3.48B | 0.00 | 144.85M | 75.37M |
| Selling & Marketing | 11.30B | 10.27B | 8.85B | 7.43B | 8.07B | 7.38B | 6.33B | 5.68B | 5.72B | 5.57B | 4.48B | 3.85B | 3.17B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.60B | 859.44M |
| SG&A | 16.15B | 16.41B | 14.40B | 13.22B | 14.14B | 13.49B | 12.18B | 10.21B | 7.87B | 7.73B | 6.07B | 5.21B | 5.70B | 5.92B | 4.88B | 4.68B | 3.48B | 0.00 | 1.74B | 934.81M |
| Other Expenses | 0.00 | 450.00M | 97.30M | 40.30M | 14.00M | 24.60M | 22.30M | 4.30M | 3.50M | 9.80M | 1.60M | 8.30M | -59.98M | 3.39B | 3.73B | 2.95B | 4.20B | 6.43B | 5.00K | 16.00K |
| Operating Expenses | 21.42B | 45.94B | 41.12B | 38.23B | 40.09B | 37.72B | 31.40B | 27.00B | 23.62B | 22.75B | 17.79B | 14.54B | 11.65B | 10.71B | 9.81B | 8.75B | 8.66B | 7.20B | 5.19B | 2.99B |
| Cost & Expenses | 80.72B | 73.29B | 66.49B | 60.58B | 62.61B | 60.93B | 49.17B | 45.88B | 40.10B | 37.49B | 30.80B | 24.22B | 21.47B | 17.67B | 15.52B | 14.11B | 11.86B | 11.74B | 8.84B | 4.92B |
| Interest Income | 114.80M | 147.80M | 71.50M | 50.70M | 79.60M | 164.10M | 66.60M | 48.50M | 60.00M | 145.80M | 274.20M | 338.10M | 328.30M | 265.94M | 0.00 | 0.00 | 0.00 | 36.93M | 38.15M | 10.81M |
| Interest Expense | 3.54B | 3.33B | 2.53B | 3.56B | 4.48B | 5.01B | 3.05B | 2.03B | 1.81B | 1.56B | 342.40M | 257.90M | 394.54M | 120.57M | 165.09M | 190.13M | 196.43M | 198.95M | 99.54M | 37.92M |
| Depreciation & Amortization | 7.95B | 7.02B | 6.62B | 6.57B | 6.52B | 6.14B | 4.09B | 2.93B | 2.46B | 1.91B | 870.00M | 826.90M | 817.29M | 625.58M | 660.86M | 422.80M | 388.31M | 328.71M | 255.18M | 187.15M |
| EBITDA | 35.01B | 28.83B | 21.43B | 25.37B | 22.89B | 16.80B | 16.56B | 15.89B | 27.65B | 10.20B | 10.87B | 6.98B | 4.80B | 4.44B | 4.30B | 2.70B | 2.08B | 1.58B | 1.11B | 793.74M |
| EBITDA Ratio | 33.01% | 30.51% | 31.07% | 32.02% | 29.09% | 26.82% | 27.17% | 27.11% | 44.14% | 27.72% | 23.77% | 23.98% | 21.44% | 19.67% | 22.43% | 16.08% | 15.32% | 12.46% | 11.63% | 14.45% |
| Operating Income | 25.34B | 21.40B | 17.69B | 18.23B | 15.19B | 13.69B | 9.41B | 10.84B | 25.10B | 8.29B | 9.53B | 6.26B | 4.48B | 3.55B | 3.64B | 2.20B | 1.69B | 1.25B | 831.26M | 557.47M |
| Operating Income Ratio | 23.89% | 22.61% | 21.02% | 23.11% | 19.52% | 18.34% | 16.06% | 19.11% | 38.50% | 18.11% | 23.62% | 20.55% | 17.26% | 16.72% | 18.98% | 13.49% | 12.45% | 9.64% | 8.59% | 10.18% |
| Total Other Income/Expenses | -1.81B | -2.66B | -5.32B | -3.05B | -3.32B | -7.81B | -96.40M | 42.30M | -1.88B | 1.10B | -1.09B | -448.00M | -827.98M | -120.57M | -165.09M | -277.72M | -196.43M | -162.02M | -61.39M | 11.21M |
| Income Before Tax | 23.52B | 18.47B | 12.26B | 15.26B | 11.87B | 5.62B | 9.31B | 10.88B | 23.64B | 9.40B | 8.44B | 5.82B | 3.59B | 3.43B | 3.47B | 1.92B | 1.49B | 1.09B | 777.04M | 568.68M |
| Income Before Tax Ratio | 22.18% | 19.52% | 14.56% | 19.35% | 15.25% | 7.53% | 15.89% | 19.18% | 36.26% | 20.53% | 20.93% | 19.08% | 13.82% | 16.15% | 18.12% | 11.79% | 11.00% | 8.40% | 8.03% | 10.38% |
| Income Tax Expense | 6.96B | 6.02B | 4.49B | 2.74B | 1.62B | 1.25B | 2.53B | 1.55B | 6.41B | 1.89B | 1.80B | 1.47B | 723.15M | 725.09M | 1.16B | 78.16M | 144.22M | 155.24M | 187.83M | 81.06M |
| Net Income | 16.56B | 12.45B | 7.77B | 12.52B | 10.25B | 4.36B | 6.78B | 9.34B | 17.22B | 7.51B | 6.64B | 4.33B | 2.84B | 2.70B | 2.31B | 1.84B | 1.35B | 935.13M | 508.63M | 487.62M |
| Net Income Ratio | 15.62% | 13.16% | 9.23% | 15.87% | 13.17% | 5.85% | 11.58% | 16.46% | 26.42% | 16.40% | 16.46% | 14.20% | 10.95% | 12.73% | 12.07% | 11.31% | 9.94% | 7.20% | 5.26% | 8.90% |
| EPS | 48.94 | 36.79 | 22.96 | 36.99 | 30.28 | 12.89 | 20.04 | 27.59 | 51.21 | 22.19 | 19.61 | 12.79 | 8.39 | 7.98 | 6.83 | 5.45 | 3.98 | 2.76 | 1.50 | 1.44 |
| EPS Diluted | 48.94 | 36.79 | 22.96 | 36.99 | 30.28 | 12.89 | 20.04 | 27.59 | 51.21 | 22.19 | 19.61 | 12.79 | 8.39 | 7.98 | 6.83 | 5.45 | 3.98 | 2.76 | 1.50 | 1.44 |
| Weighted Avg Shares Out | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.44M | 338.44M | 338.44M | 338.44M | 338.44M | 338.44M | 338.44M |
| Weighted Avg Shares Out (Dil) | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.45M | 338.44M | 338.44M | 338.44M | 338.44M | 338.44M | 338.44M | 338.44M |
Source: https://incomestatements.info
Category: Stock Reports